Bindarit (AF 2838)
/ Angelini Group
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
55
Go to page
1
2
3
November 24, 2025
Bindarit-loaded hydrogel sustained-release system alleviates periodontitis in mice via CC motif chemokine ligand 2-dependent monocyte chemotaxis.
(PubMed, J Control Release)
- "All these effects were reversed by CCL2 overexpression, confirming a CCL2-dependent mechanism. This study establishes a promising immunomodulatory strategy for periodontitis, highlighting the potential of sustained-release hydrogels in treating inflammatory diseases."
Journal • Preclinical • Dental Disorders • Immune Modulation • Immunology • Inflammation • Osteoporosis • Periodontitis • CCL2
August 17, 2025
Wogonin modulates macrophage polarization and inflammatory signaling through the LSD1-p65 axis to alleviate osteoarthritis.
(PubMed, Phytomedicine)
- "Wogonin alleviates OA pathology by targeting the LSD1-p65 axis to balance macrophage polarization and mitigate inflammatory cascades. Its dual modulation of immune responses and tissue repair highlights therapeutic potential, warranting validation in large animal models and human OA tissues for clinical translation. This work positions wogonin as a novel disease-modifying agent for OA."
Journal • Immunology • Osteoarthritis • Pain • Rheumatology • CCL2 • CD163 • IL6 • KDM1A • NFKBIA • TNFA
August 06, 2025
Endothelial PRMT7 prevents dysfunction, promotes revascularization and enhances cardiac recovery post-myocardial infarction.
(PubMed, Exp Mol Med)
- "Conversely, PRMT7 overexpression or treatment with the PRMT7-inducing drug bindarit restores EC function, suppresses ER stress and enhances revascularization and cardiac repair after MI. These findings establish endothelial PRMT7 as a critical regulator of EC survival and function, highlighting its potential as a therapeutic target to mitigate ER stress and improve post-MI cardiac recovery."
Journal • Cardiovascular • Fibrosis • Immunology • Myocardial Infarction • Oncology • PRMT7 • TNFA
July 10, 2025
Mesenchymal stromal cells highly expressing Sca-1 promote breast cancer lung metastasis through recruiting myeloid cells.
(PubMed, Cell Death Dis)
- "Inhibition of macrophage chemotaxis by Bindarit, an inhibitor of CCL2/7/8 transcription, decreased the lung tumor burden induced by Sca-1high MSCs. Using Ccr5-/- mice, it was further confirmed that Sca-1high LMSCs promote tumorigenesis by recruiting macrophages, further supporting that the increased recruitment of macrophages mediates the pro-metastasis effect of Sca-1high LMSCs. Collectively, this study demonstrated that Sca-1high LMSCs and their effectors could be targeted to inhibit breast cancer metastasis to the lung."
Journal • Breast Cancer • Lung Cancer • Oncology • Solid Tumor • CCL2 • CXCL1
June 24, 2025
CCL2 Inhibitor Bindarit Improve Postoperative Cognitive Function by Attenuating Pericyte Loss-Related Blood-Brain Barrier Disruption and Neuroinflammation.
(PubMed, Mediators Inflamm)
- "This study demonstrates that the CCL2 inhibitor Bindarit significantly reduces the incidence of PND by preventing PC loss, thereby protecting the BBB and alleviating neuroinflammation. These findings suggest that targeting CCL2 could be a potential therapeutic strategy for preventing and treating PND."
Journal • Anesthesia • CNS Disorders • Cognitive Disorders • Developmental Disorders • Inflammation • Musculoskeletal Diseases • Orthopedics • CCL2 • CLDN5 • GFAP • OCLN
June 07, 2025
A pH-responsive guanidino-based covalent organic framework nanodrugs for enhanced neuroprotection against subarachnoid hemorrhage by targeting NLRP3 inflammasome.
(PubMed, Biomaterials)
- "Bindarit, a β-blocker with anti-inflammatory properties, has demonstrated potential in mitigating NLRP3-mediated pyroptosis...The development of B@COFDT-R constitutes a substantial advancement in the treatment of SAH. Through the enhancement of drug delivery mechanisms and the targeted modulation of critical inflammatory pathways, this nanocarrier holds the potential to significantly improve therapeutic outcomes for patients suffering from SAH."
Journal • Cardiovascular • Hematological Disorders • Inflammation • Subarachnoid Hemorrhage • NLRP3
May 20, 2025
Engineering blood-brain barrier microphysiological systems to model Alzheimer's disease monocyte penetration and infiltration.
(PubMed, Biomater Sci)
- "Moreover, we also tested the interventions including Minocycline and Bindarit, and found they can effectively inhibit AD monocyte infiltration, subsequently reducing neuroinflammation and neuronal apoptosis. We believe these scalable and user-friendly BBB-MPS models may hold promising potential in modeling and advancing therapeutics for neurodegenerative and neuroinflammatory diseases."
Journal • Alzheimer's Disease • CNS Disorders • Dementia • Inflammation
January 27, 2025
Elucidating the therapeutic potential of indazole derivative bindarit against K-ras receptor: An in-silico analysis using molecular dynamics exploration.
(PubMed, Biochem Biophys Rep)
- "Consequently, further downstream signalling of the K-Ras pathway would be blocked and this could lead to the inhibition of K-Ras dependent cancer cell proliferation. However, further validation of present study can be done through experimental assay such as cytotoxic and protein expression analysis."
Journal • Colon Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • KRAS
January 12, 2025
Bindarit attenuates neuroinflammation after subarachnoid hemorrhage by regulating the CCL2/CCR2/NF-κB pathway.
(PubMed, Brain Res Bull)
- "Endogenous CCL2 expression was upregulated in the rat SAH model. Bindarit improved neurological functions and reduced neuroinflammation by regulating the CCL2/CCR2/NF-κB pathway in early brain injury after SAH."
Journal • CNS Disorders • Hematological Disorders • Inflammation • Subarachnoid Hemorrhage • Vascular Neurology • CCL2 • CCR2
December 18, 2024
Circulating monocyte adhesion repairs endothelium-denuded injury through downstream of kinase 3-mediated endothelialization.
(PubMed, Biochim Biophys Acta Mol Basis Dis)
- "However, this process was inhibited by the CCR2B inhibitor INCB3344...Bindarit, a selective MCP1 inhibitor, suppressed endothelialization following CCAED surgery in WT mice but not in DOK3-/- mice. In conclusion, endothelialization mediated by circulating monocytes repairs endothelium-denuded injury to compensate for endothelial functions through MCP1/DOK3/CCR2B/Ca2+ signaling. Our findings indicate that circulating monocyte adhesion is an important endothelial wound healing mechanism."
Journal • Cardiovascular • Hematological Disorders • Thrombosis • CCL2 • CCR2
December 21, 2024
Impact of Bindarit, a CCL2 Chemokine Synthesis Inhibitor, on Macrophage-Based Biofouling and Continuous Glucose Monitoring in vivo.
(PubMed, Biosens Bioelectron X)
- "These results not only confirm the major role monocytes/macrophages play, but directly demonstrate that CCL2 drives Mo/MQ recruitment and biofouling of glucose sensors in vivo. These findings support future studies incorporating Mo/MQ migration/chemotaxis inhibitors, like CCL2, on sensor coatings to improve glucose sensor accuracy and lifespan in vivo."
Journal • Preclinical • Diabetes • Fibrosis • Immunology • Inflammation • Metabolic Disorders • CCL2 • CCR2
December 13, 2024
Unraveling morphine tolerance: CCL2 induces spinal cord apoptosis via inhibition of Nrf2 signaling pathway and PGC-1α-mediated mitochondrial biogenesis.
(PubMed, Brain Behav Immun)
- "Our data emphasize that chemokine CCL2 inhibited the Nrf2 signaling pathway and PGC-1α-mediated mitochondrial biogenesis, alleviating the occurrence of apoptosis in spinal cord, thereby participating in morphine tolerance. This may provide new targets for the treatment of morphine tolerance."
Journal • Inflammation • Neuralgia • Pain • CCL2
November 20, 2024
Exploring and Validating the Mechanism of Ulinastatin in the Treatment of Sepsis-Associated Encephalopathy Based on Transcriptome Sequencing.
(PubMed, J Inflamm Res)
- "A total of 106 hub - gene - related drugs were predicted, among which BINDARIT - CCL2 and LIFITEGRAST - ICAM1 showed particularly high affinities. In conclusion, ICAM-1, IRF7, IL-1β, CCL2, IL-6, and SOCS3 were identified as potential therapeutic targets in SAE mice treated with UTI. This study offers theoretical support for UTI as a treatment option for SAE."
Journal • CNS Disorders • Infectious Disease • Septic Shock • CCL2 • ICAM1 • IL1B • IL6 • IRF7 • SOCS3
November 16, 2024
Choroid plexus CCL2‒CCR2 signaling orchestrates macrophage recruitment and cerebrospinal fluid hypersecretion in hydrocephalus.
(PubMed, Acta Pharm Sin B)
- "Furthermore, the administration of CCR2 antagonist (INCB 3284) reduces ChP macrophage accumulation and ventriculomegaly. This study not only unveils the ChP CCL2‒CCR2 signaling in the pathophysiology of hydrocephalus but also unveils Bindarit as a promising therapeutic choice for the management of posthemorrhagic hydrocephalus."
Journal • CNS Disorders • Hematological Disorders • Inflammation • Ventriculomegaly • CCL2 • CCR2 • TNFA • TNFRSF1A
July 04, 2024
CCL2 promotes EGFR-TKIs resistance in non-small cell lung cancer via the AKT-EMT pathway.
(PubMed, Acta Biochim Biophys Sin (Shanghai))
- "Conversely, CCL2 suppression by CCL2 synthesis inhibitor, bindarit, or CCL2 knockdown can reverse this resistance...In summary, CCL2 promotes the development of acquired EGFR-TKIs resistance and EMT while activating AKT signaling in NSCLC. These insights suggest a promising avenue for the development of CCL2-targeted therapies that prevent EGFR-TKIs resistance in NSCLC."
Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CCL2
June 22, 2024
Bindarit treatment results in minor effects in the FKRP-P448Lneo- mutant mouse
(New Directions 2024)
- No abstract available
Preclinical • Fibrosis • Immunology • Inflammation
March 29, 2024
CCL2-CCR2 AXIS MEDIATES DECIDUAL MONOCYTE/MACROPHAGE INFILTRATION AND INFLAMMATION IN OBSTETRIC ANTIPHOSPHOLIPID SYNDROME
(EULAR 2024)
- "The monocyte/macrophage infiltration and inflammation of blocking CCL2-CCR2 signaling in OAPS mice was investigated by bindarit, a CCL2 inhibitor, and RS504393, a CCR2 antagonist... The CCL2-CCR2 axis mediates monocyte/macrophage infiltration from peripheral blood to decidua, and subsequent inflammation, among OAPS. We provide a new insight into the mechanism and therapeutic target for OAPS."
Genetic Disorders • Hematological Disorders • Inflammation • Obstetrics • CCL2 • CCR2 • IFNG • TNFA
March 26, 2024
Single-cell RNA sequencing reveals recruitment of the M2-like CCL8high macrophages in Lewis lung carcinoma-bearing mice following hypofractionated radiotherapy.
(PubMed, J Transl Med)
- "Hypofractionated radiotherapy enhances the infiltration of CCL8high macrophages and amplifies their roles in macrophage recruitment through the CCL signaling pathway, leading to an immunosuppressive tumor microenvironment. These findings highlight the potential of targeting TAMs and introduces a novel combination to improve the efficacy of hypofractionated radiotherapy."
Journal • Preclinical • Lung Cancer • Oncology • Solid Tumor • CCL2 • CCL8 • MRC1
December 13, 2023
Chemokine CCL2 promotes cardiac regeneration and repair in myocardial infarction mice via activation of the JNK/STAT3 axis.
(PubMed, Acta Pharmacol Sin)
- "Conversely, treatment with a selective CCL2 synthesis inhibitor Bindarit (30 μM) suppressed both CCL2 expression and cardiomyocyte proliferation in P1 neonatal rat ventricle myocytes (NRVMs). We demonstrated in NRVMs that the CCL2 stimulated cardiomyocyte proliferation through STAT3 signaling: treatment with rCCL2 (100 ng/mL) significantly increased the phosphorylation levels of STAT3, whereas a STAT3 phosphorylation inhibitor Stattic (30 μM) suppressed rCCL2-induced cardiomyocyte proliferation. In conclusion, this study suggests that CCL2 promotes cardiac regeneration via activation of STAT3 signaling, underscoring its potential as a therapeutic agent for managing MI and associated heart failure."
Journal • Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • CCL2
December 14, 2023
Astragaloside IV alleviates LPS-induced cardiomyocyte hypertrophy and collagen expression associated with CCL2-mediated activation of NF-κB signaling pathway.
(PubMed, Biochem Biophys Res Commun)
- "Additionally, a classical inhibitor of CCL2 (bindarit) were used to further explore whether the anti-inflammatory effect of AS-IV was dependent on this chemokine. Our results indicated that AS-IV could exert a potent inhibitory effect on CCL2 expression and down-regulated NF-κB signaling pathway in a CCL2-dependent manner. These findings provided a scientific basis for promoting the treatment of HF with AS-IV."
Journal • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • Inflammation • CCL2
September 12, 2023
CCL2 is a key regulator and therapeutic target for periodontitis.
(PubMed, J Clin Periodontol)
- "CCL2 is a pivotal chemokine that binds to CCR2 during the progression of periodontitis, and targeting CCL2 may be a feasible option for controlling periodontitis."
Journal • Dental Disorders • Inflammation • Osteoporosis • Periodontitis • CCL2 • CCL8 • CCR2 • IL1B • IL6 • TNFA • TRAP
September 08, 2023
STING signaling activation modulates macrophage polarization via CCL2 in radiation-induced lung injury.
(PubMed, J Transl Med)
- "The cGAS-STING signaling pathway plays a crucial role in regulating the recruitment and polarization of macrophages, partly through CCL2, during the pathogenesis of RILI."
Journal • Oncology • Pneumonia • Respiratory Diseases • CCL2
April 26, 2023
CCL2 is required for initiation but not persistence of HIV infection mediated neurocognitive disease in mice.
(PubMed, Sci Rep)
- "Treatment of mice prior to and during EcoHIV infection with the CCL2 transcriptional inhibitor, bindarit, prevented brain infection and NCI and reduced macrophage infection...Based on these findings we propose that HIV enters the brain mainly through infected monocytes but that resident brain cells are sufficient to maintain NCI. These findings suggest that NCI therapy must act within the brain."
Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Human Immunodeficiency Virus • Infectious Disease • CCL2 • CCR2
April 18, 2023
Bioinformatics-integrated screening of systemic sclerosis-specific expressed markers to identify therapeutic targets.
(PubMed, Front Immunol)
- "Potential RNA regulatory pathways, including MALAT1-miR-206-CCL2, let-7a-5p-IL6, and miR-196a-5p-SERPINE1, contribute to our knowledge of SSc. Furthermore, the analysis of drug-hub gene interactions predicted TIPLASININ, CARLUMAB and BINDARIT as candidate drugs for SSc."
Journal • Fibrosis • Hematological Disorders • Immunology • Scleroderma • Systemic Sclerosis • CCL2 • IL6 • ISG15 • MALAT1 • MIR206 • SERPINE1
March 01, 2023
5-Oxoproline Enhances 4-Hydroxytamoxifen-induced Cytotoxicity by Increasing Oxidative Stress in MCF-7 Breast Cancer Cells.
(PubMed, Anticancer Res)
- "5-OP enhances 4-OHT-induced cytotoxicity in ER-positive breast cancer cells under normal glucose conditions."
Journal • Breast Cancer • Diabetes • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HIF1A • MCT1
1 to 25
Of
55
Go to page
1
2
3